Effects of dapagliflozin on primary and secondary outcomes consistent for those with eGFR <60 and \u226560 mL\/min per 1.73 m2<\/sup><\/p>\n<\/h3>\n <\/b><\/p>\n <\/b><\/p>\n FRIDAY, April 29, 2022 (HealthDay News) — The effects of dapagliflozin are similar for hospitalized patients with COVID-19 with estimated glomerular filtration rate (eGFR) <60 and \u00e2\u0089\u00a560 mL\/min per 1.73 m2<\/sup>, according to a study published online April 28 in the Clinical Journal of the American Society of Nephrology<\/em>.<\/p>\n Hiddo J. L. Heerspink, Ph.D., Pharm.D., from the University Medical Center Groningen in the Netherlands, and colleagues conducted a secondary analysis of the Dapagliflozin in Respiratory Failure in Patients with COVID-19 (DARE-19) trial, which randomly assigned 1,250 hospitalized patients with COVID-19 and cardiometabolic risk factors to dapagliflozin or placebo. Dual primary outcomes (time to new or worsened organ dysfunction or death, and a hierarchical composite end point of recovery) and key secondary kidney outcomes were assessed among those with baseline eGFR <60 and \u00e2\u0089\u00a560 mL\/min per 1.73 m2<\/sup>.<\/p>\n The researchers found that across eGFR subgroups, the effect of dapagliflozin versus placebo was consistent on the primary prevention outcome (hazard ratio, 0.80; 95 percent confidence interval, 0.58 to 1.10), primary recovery outcome (win ratio, 1.09; 95 percent confidence interval, 0.97 to 1.22), and the composite kidney outcome (hazard ratio, 0.74; 95 percent confidence interval, 0.50 to 1.07; P for interaction, 0.98, 0.67, and 0.44, respectively). The effects of dapagliflozin on acute kidney injury were also similar for those with eGFR <60 mL\/min per 1.73 m2 <\/sup>(hazard ratio, 0.71; 95 percent confidence interval, 0.29 to 1.77) and \u00e2\u0089\u00a560 mL\/min per 1.73 m2<\/sup> (hazard ratio, 0.69; 95 percent confidence interval, 0.37 to 1.29). In patients with eGFR <60 and \u00e2\u0089\u00a560 mL\/min per 1.73 m2<\/sup>, dapagliflozin was well tolerated.<\/p>\n “These new data from DARE-19 reinforce the safety of dapagliflozin in acutely ill patients hospitalized with COVID-19 even in those with reduced kidney function who are at particularly high risk of acute kidney injury,” Heerspink said in a statement.<\/p>\n Several authors disclosed financial ties to pharmaceutical companies, including AstraZeneca, which manufactures dapagliflozin and funded the study.<\/p>\n Abstract\/Full Text<\/a><\/p>\n